Zobrazeno 1 - 10
of 39
pro vyhledávání: ''
Autor:
Kirsti Tiihonen, Arthur C. Ouwehand, Mika Scheinin, Marita Kailajärvi, Sanna M. Mäkelä, Sofia D. Forssten, Ville L. Langen
Publikováno v:
British Journal of Clinical Pharmacology. 87:4625-4635
AIMS Use of nonsteroidal anti-inflammatory drugs (NSAIDs) can cause damage to the gastric and duodenal mucosa. Some probiotics have proven useful in ameliorating the harmful side-effects of NSAIDs. Our aim was to evaluate whether oral administration
Autor:
Reinhard Schinzel, S Friedrich, Agnes Bosch, Nicole Winzer, Christian Ott, Roland E. Schmieder, Frank Tegtmeier
Publikováno v:
Br J Clin Pharmacol
AIMS: Reduced nitric oxide (NO) availability may adversely affect renal perfusion and glomerular filtration. The aim of the present study was to characterize in detail the pharmacological effects of VAS203, an inhibitor of NO synthase, on renal haemo
Autor:
Ming Dauh Wang, Stephen J. Nicholls, Ellen A. Cannady, Stuart Friedrich, Jessica Rehmel, Jeffrey G. Suico, Kathryn A. Krueger
Publikováno v:
British Journal of Clinical Pharmacology
Aims Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor under development for reducing cardiovascular events in patients with high risk vascular disease. CETP inhibitors are likely to be utilized as ‘add-on’ therapy to statins i
Publikováno v:
British Journal of Clinical Pharmacology. 68:61-76
Omalizumab, a subcutaneously administered anti-IgE antibody, is effective for moderate-to-severe persistent allergic asthma. The aims were to (i) describe the population pharmacodynamics of free IgE with a mechanism-based, nonlinear, omalizumab-IgE b
Publikováno v:
British Journal of Clinical Pharmacology. 67:309-315
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Obesity is a significant and growing problem for which many patients seek pharmacological intervention. • Orlistat, a lipase inhibitor, is licensed for the treatment of obesity. • In combination with d
Autor:
Mark E. Bangs, Yi M. Cui, Amanda J. Long, Eunice Yuen, Choo H. Teng, Ying Zhou, Alan X. Pan, Xia Zhao, Stephen D. Wise, Kwee P. Yeo
Publikováno v:
British Journal of Clinical Pharmacology. 64:445-449
What is already known about this subject • Atomoxetine is a cytochrome P450 2D6 (CYP2D6) substrate and its pharmacokinetics has been characterized in a predominantly White population during clinical development. • There are scant East Asian pharm
Autor:
Adam F. Cohen, Margriet Ouwens, Marieke de Kam, Rik C. Schoemaker, Michiel J. B. Kemme, Hans Romijn, Martijn B A van Doorn, Ewoud J. van Hoogdalem, Richard Jones, K. Burggraaf
Publikováno v:
British Journal of Clinical Pharmacology. 62:391-402
Aims Thiazolidinediones (TZDs) not only enhance cellular glucose transport but are reported to have potent anti-inflammatory effects. These effects may play an important role in the insulin sensitizing mechanism, and possibly precede the effects on p
Autor:
Takaki Tokairin, Koichi Otani, Norio Yasui-Furukori, Toshiaki Aoshima, Takashi Fukasawa, Yoshimasa Inoue, Tomonori Tateishi, Akihito Suzuki
Publikováno v:
British Journal of Clinical Pharmacology. 60:172-175
Aims To obtain in vivo evidence for the involvement of cytochrome P450 (CYP) 3A4 in the metabolism of brotizolam. Methods Fourteen healthy male volunteers received erythromycin 1200 mg day−1 or placebo for 7 days in a double-blind randomized crosso
Autor:
Norio Yasui-Furukori, Sunao Kaneko, Tomonori Tateishi, Yoshimasa Inoue, Gen Yoshiya, Taku Nakagami, Takenori Takahata
Publikováno v:
British Journal of Clinical Pharmacology. 57:487-494
Omeprazole is mainly metabolized by the polymorphic cytochrome P450 (CYP) 2C19. The inhibitory effect of fluvoxamine, an inhibitor of CYP2C19 as well as CYP1A2, on the metabolism of omeprazole was compared between different genotypes for CYP2C19.Eigh
Publikováno v:
British Journal of Clinical Pharmacology. 45:559-566
Aims To investigate the relationship in patients with heart failure between BP response to the first dose of ACE inhibitor and (1) plasma drug concentration and (2) baseline clinical and laboratory variables. Methods We studied individual placebo-cor